Guselkumab for the Treatment of Psoriasis

Scanning the Immunopathogenesis of Psoriasis

(2018) Andrea Chiricozzi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease

(2017) Parakkal Deepak et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis

(2017) G. Girolomoni et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases

(2016) George E. Fragoulis et al.   Annual Review of Medicine

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

(2016) Yanli Zhuang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

(2016) Bruce E. Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-12 protects from psoriasiform skin inflammation

(2016) Paulina Kulig et al.   Nature Communications

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

The Immunopathogenesis of Psoriasis

(2015) Jaehwan Kim et al.   DERMATOLOGIC CLINICS

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation

(2015) Joseph R. Maxwell et al.   IMMUNITY

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

(2015) Diamant Thaçi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tavaborole: First Global Approval

(2014) Anthony Markham   DRUGS

Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?

(2014) Andrea Chiricozzi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

(2014) Howard Sofen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications

(2010) Therwa Hamza et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

(2009) L. van der Fits et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET